Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AKRO Akero Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: AKRO
Price (delayed)
$49.65
Market cap
$3.96B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.75
Enterprise value
$3.81B
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein,
Highlights
AKRO's equity is up by 44% since the previous quarter and by 28% year-on-year
AKRO's net income has shrunk by 50% YoY and by 7% QoQ
Akero Therapeutics's quick ratio has decreased by 46% YoY and by 13% QoQ
Key stats
What are the main financial stats of AKRO
Market
Valuations
Earnings
Shares outstanding
79.72M
Market cap
$3.96B
Enterprise value
$3.81B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.65
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$306.35M
Net income
-$269.44M
EBIT
-$264.61M
EBITDA
-$264.34M
Free cash flow
-$262.63M
Per share
Balance sheet
Liquidity
EPS
-$3.75
EPS diluted
-$3.75
Free cash flow per share
-$3.34
Book value per share
$13.61
Revenue per share
$0
TBVPS
$14.69
Total assets
$1.16B
Total liabilities
$72M
Debt
$35.93M
Equity
$1.08B
Working capital
$670.71M
Debt to equity
0.03
Current ratio
16.8
Quick ratio
16.17
Net debt/EBITDA
0.57
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.4%
Return on equity
-32%
Return on invested capital
-42.4%
Return on capital employed
-23.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKRO stock price
How has the Akero Therapeutics stock price performed over time
Intraday
3.37%
1 week
7.1%
1 month
8.86%
1 year
171.16%
YTD
78.47%
QTD
22.65%
Financial performance
How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$306.35M
Net income
-$269.44M
Gross margin
N/A
Net margin
N/A
Akero Therapeutics's operating income has plunged by 50% YoY and by 7% from the previous quarter
AKRO's net income has shrunk by 50% YoY and by 7% QoQ
Price vs fundamentals
How does AKRO's price correlate with its fundamentals
Growth
What is Akero Therapeutics's growth rate over time
Valuation
What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
3.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has decreased by 16% YoY
AKRO's equity is up by 44% since the previous quarter and by 28% year-on-year
The stock's P/B is 40% above its last 4 quarters average of 2.6 but 3.9% below its 5-year quarterly average of 3.8
Efficiency
How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on invested capital has increased by 26% YoY and by 22% QoQ
Akero Therapeutics's return on equity has decreased by 15% YoY
The ROA has contracted by 14% YoY
Dividends
What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKRO.
Financial health
How did Akero Therapeutics financials performed over time
Akero Therapeutics's quick ratio has decreased by 46% YoY and by 13% QoQ
The current ratio is down by 44% year-on-year and by 13% since the previous quarter
AKRO's debt is 97% smaller than its equity
AKRO's equity is up by 44% since the previous quarter and by 28% year-on-year
The debt to equity has contracted by 40% from the previous quarter and by 25% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.